Pulmohyperta

Desctription

Pulmohyperta tablets contains bosentan and belong to a group of medicines called “endothelin receptor antagonist”.

Bosentan is a dual endothelin receptor antagonist (ERA) with affinity for both endothelin A and B (ETA and ETB) receptors. Bosentan decreases both pulmonary and systemic vascular resistance resulting in increased cardiac output without increasing heart rate.

Indications

Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in:
• Primary (idiopathic and heritable) pulmonary arterial hypertension
• Pulmonary arterial hypertension secondary to scleroderma without significant interstitial pulmonary disease
• Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s physiology
Some improvements have also been shown in patients with pulmonary arterial hypertension WHO functional class II.

Subject to medical prescription

Pharmaceutical form: Pulmohyperta 62,5 mg film-coated tablets x 56 tablets

NHIF code:

ICD: I27.0; M34.0, M34.1, M34.2, M34.8;  Q21.8

Pharmaceutical form: Pulmohyperta 125 mg film-coated tablets x 56 tablets

NHIF code: CG192

ICD: I27.0; M34.0, M34.1, M34.2, M34.8;  Q21.8

АТС: C02KX01